SCHEMBL6499730

SCHEMBL6499730

CCSc1nc(-c2ccc(S(=O)(=O)Cl)c(OC)c2)cc2nccn12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 5/20 0.42
MAP4K2 Q12851 4/20 0.42
MAP4K4 O95819 2/20 0.42
PKN2 Q16513 2/20 0.42
AURKB Q96GD4 2/20 0.42
SLK Q9H2G2 2/20 0.42
CDC7 O00311 1/20 0.42
PLK4 O00444 1/20 0.42
DYRK3 O43781 1/20 0.42
ROCK2 O75116 1/20 0.42
PRKD3 O94806 1/20 0.42
CDK1 P06493 1/20 0.42
CSF1R P07333 1/20 0.42
MET P08581 1/20 0.42
KIT P10721 1/20 0.42
PHKG2 P15735 1/20 0.42
CDK2 P24941 1/20 0.42
MAPK1 P28482 1/20 0.42
FLT3 P36888 1/20 0.42
CLK2 P49760 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6497433 0.85 MEN1 (0.53) SYKMAP4K2MAP4K4PKN2AURKB
SCHEMBL6495708 0.85 MCOLN3 (0.45) SYKMAP4K2MAP4K4PKN2AURKB
SCHEMBL6495558 0.83 CXCL12 (0.45) SYKMAP4K2MAP4K4PKN2AURKB
SCHEMBL6505068 0.81 SYK (0.44) SYKMAP4K2MAP4K4PKN2AURKB
SCHEMBL6498406 0.81 SYK (0.43) SYKMAP4K2MAP4K4PKN2AURKB
SCHEMBL6498410 0.81 SYK (0.45) SYKMAP4K2MAP4K4PKN2AURKB
SCHEMBL6495094 0.80 MAOB (0.45) SYKMAP4K2MAP4K4PKN2AURKB
SCHEMBL6495281 0.78 IGF1R (0.47) SYKMAP4K2MAP4K4PKN2AURKB
SCHEMBL6497718 0.76 SYK (0.43) SYKMAP4K2MAP4K4PKN2AURKB
SCHEMBL6529655 0.76 MAP4K2 (0.51) MAP4K2DYRK1ACLK4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6911443-B2 Imidazopyrimidine derivatives and triazolopyrimidine derivatives BAYER AKTIENGESELLSCHAFT (DE) 2005-06-28 US disclosed
EP-1278750-B1 IMIDAZOPYRIMIDINE DERIVATIVES AND TRIAZOLOPYRIMIDINE DERIVATIVES BAYER HEALTHCARE AG (DE) 2004-08-04 EP disclosed
US-20040054179-A1 Imidazopyrimidine derivatives and triazolopyrimidine derivatives BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-03-18 US disclosed
EP-1278750-A1 IMIDAZOPYRIMIDINE DERIVATIVES AND TRIAZOLOPYRIMIDINE DERIVATIVES Bayer Aktiengesellschaft (DE) 2003-01-29 EP disclosed
WO-2001083485-A1 IMIDAZOPYRIMIDINE DERIVATIVES AND TRIAZOLOPYRIMIDINE DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2001-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040054179-A1 Imidazopyrimidine derivatives and triazolopyrimidine derivatives XRCC6, XRN2, HRH2 SYK 1025/4885MAP4K2 2126/4885MAP4K4 2194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.